Larimar Therapeutics, Inc. (LRMR) stock analysis

In our weekly check, Larimar Therapeutics, Inc. is graded F (A to F). Of 18 checks on debt, profit, cash flow and trend: 5 pass, warnings: 3, red flags: 10.

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as LRMR.

What our checks show for LRMR

Red flags

Warning signs

Strengths

Similar companies

KYTX · BNTC · MPLT · XFOR · ALT · PEPG

Questions

What grade does Larimar Therapeutics, Inc. (LRMR) have?

In our weekly check, Larimar Therapeutics, Inc. is graded F (A to F). Of 18 checks on debt, profit, cash flow and trend: 5 pass, warnings: 3, red flags: 10. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of LRMR stock?

This week's biggest flags for Larimar Therapeutics, Inc.: Weak EPS forecast, Margins expected to shrink, Weak EPS growth. In total 13 of 18 checks show a warning or a red flag.

What does Larimar Therapeutics, Inc. do?

Larimar Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as LRMR.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis